SIRIO Pharma Expands Operations with €16 Million Packaging Investment

• SIRIO Pharma has invested €16 million in a new packaging facility at its Pritzwalk campus in Germany, increasing its total investment at the site to €19 million over five years.

• The facility features advanced bottling and blistering lines, enabling rapid processing and support for bulk supply and private label options.

SIRIO Pharma, a global contract development and manufacturing organisation (CDMO), has announced a €16 million investment in a new packaging facility at its Pritzwalk campus near Berlin, Germany. This expansion brings the company’s total investment at the site to €19 million over the past five years.

The newly constructed facility includes automated bottling and blistering lines, designed to accommodate both bulk supply and private label products. This enhancement allows SIRIO to provide comprehensive services that span from formulation development to final product packaging, thus facilitating the efficient transfer of pharmaceutical and nutraceutical softgels from the adjacent manufacturing site.

Equipped with advanced process-control technologies, the packaging lines comply with pharmaceutical-grade Good Manufacturing Practices (GMP) standards. They support rapid processing, with production-to-delivery times as short as three weeks. The facility includes a high-speed bottling line capable of producing up to 5 million bottles annually and a second line that can fill 20 million blister packs each year.

To maintain stringent quality control, the new lines are outfitted with visual inspection systems and in-line process control technologies. These systems monitor critical parameters such as physical appearance, product weight, and metal detection, ensuring high standards are upheld throughout the packaging process.

Sara Lesina, General Manager of SIRIO Europe & Americas, stated, “With our state-of-the-art packaging facility, we now offer full-service, pharmaceutical-grade softgel development in Germany.” This investment reflects SIRIO Pharma’s commitment to advancing its manufacturing technology and supporting the increasing demand for high-quality pharmaceutical products.